Compare THM & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THM | SENS |
|---|---|---|
| Founded | 1978 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Machinery/Components |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 402.9M | 397.1M |
| IPO Year | 2002 | 2014 |
| Metric | THM | SENS |
|---|---|---|
| Price | $1.61 | $9.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | ★ 1.5M | 581.7K |
| Earning Date | 11-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $82.21 |
| Revenue Next Year | N/A | $55.63 |
| P/E Ratio | $280.00 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $1.07 | $4.79 |
| 52 Week High | $3.65 | $10.64 |
| Indicator | THM | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 37.75 | 57.37 |
| Support Level | N/A | $5.07 |
| Resistance Level | $2.88 | $10.13 |
| Average True Range (ATR) | 0.19 | 0.72 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 50.00 | 93.05 |
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.